FDA adcomm votes unanimously against Reata's potential Alport syndrome treatment
The US FDA’s Cardiovascular and Renal Drugs Advisory Committee on Wednesday voted 13-0 that the agency should not approve Reata Pharmaceuticals’ bardoxolone methyl capsules as a treatment to slow the progression of chronic kidney disease in those with the rare Alport syndrome.
The lopsided vote follows similar comments from FDA on Monday, which painted an overwhelmingly negative opinion on Reata’s $RETA potential drug, according to briefing documents released ahead of today’s meeting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.